Eigen RadarEconomics
Analysis

Windward Bio closes Nasdaq debut above its offer price

Swiss biotechnology company Windward Bio began trading on Nasdaq on 13 November. Investor Qiming Venture Partners put the first closing price at 28.50 dollars, against a 17 dollar offer price. The public offering carried expected gross proceeds of 175 million dollars, with a separate Sanofi private placement bringing the combined financing to 225 million dollars.

Economics & Markets··Night
Company staff applaud under falling confetti in a stock-exchange studio on listing day, a rising line on the screen behind. Windward Bio shares closed their Nasdaq debut above the offer price.

The Nasdaq debut follows private funding rounds

Windward Bio, a Swiss biotechnology company developing treatments for immune-related diseases, started trading on the Nasdaq stock exchange on 13 November. Its shares were offered at 17 dollars each.[1], [2]

Qiming Venture Partners, an investor in the company, said the shares ended their first trading session at 28.50 dollars, approximately 68 per cent above the offer price. It put the company’s equity market value at approximately 1.69 billion dollars. Qiming had invested in the Series A funding round in 2025, the Series B round in 2026 and the public offering.[1]

Public offering and Sanofi placement bring financing

The public offering was expected to raise 175 million dollars in gross proceeds from approximately 10.3 million shares. A separate private placement with Sanofi, the pharmaceutical group, brought the combined financing to 225 million dollars. The public share sale and private investment formed separate components of the financing accompanying the listing.[2]

Licensed antibody programmes underpin the business

Founded in 2024, Windward is developing antibody treatments for respiratory and skin diseases. Its lead candidate was licensed from drug developers Kelun and Harbour BioMed, with Greater China and certain Asian markets excluded from the rights described by Qiming. Another antibody candidate was licensed from Qyuns, a biotechnology developer. The company remains at the clinical development stage.[1]

References

  1. News sourceQiming Venture PartnersWindward Bio ends Nasdaq debut above its offer price↩1↩2↩3
  2. News sourceBioSpaceWindward Bio raises 175 million dollars in IPO↩1↩2